c12) United States Patent
`Carter et al.
`
`I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
`US006407213B1
`US 6,407,213 Bl
`Jun.18, 2002
`
`(10) Patent No.:
`(45) Date of Patent:
`
`(54) METHOD FOR MAKING H UMANIZED
`ANTIBODIES
`
`(75)
`
`Ioveotors: Pa ul J. C arter; Leonard G. Presta,
`both of Sao Fraocisco, CA (US)
`
`(73) Assignee: Genentech, Inc., Soutb San Francisco,
`CA (US)
`
`(*) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted u nder 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.:
`
`(22) PCT Filed:
`
`08/146,206
`Jun. 15, 1992
`
`(86) PCT No.:
`
`PCT/US92/05126
`
`§ 371 (c)(l),
`(2), (4) Date: Nov. 17, 1993
`
`Related U.S. Application Data
`
`(63) Continuation-in-part of application No. 01n 15,272, filed on
`Ju11. 14, 1991, now abandoned.
`
`(51)
`(52)
`
`(58)
`
`(56)
`
`Int. C l.7
`•••••. •. ••••••••••. . •• . •••• .•• .•••• . ••••••.••••• C07K 16/ 00
`U.S. Cl. .................. 530/387.3; 435/69.6; 435/69.7;
`435/70.21; 435/91; 536/23.53; 424/133.1
`Field of' Sear ch ............................... 435/69.6, 69.7,
`435/70.21, 91, 172.2, 240.1, 240.27, 252.3,
`320.l, 328; 536/23.53; 424/133.1; 530/387.3
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,816,567 A
`4,845,198 A
`5,132,405 A
`5,225,539 A
`5,530,101 A
`5,558,864 A
`5,585,089 A
`5,677,171 A
`5,693,762 A
`5,714,350 A
`5,772,997 A
`5,821,337 A
`5,834,598 A
`5,859,205 A
`
`3/1989 CabiJly ei al.
`........... 530/388.22
`7/1989 Urdal et al.
`7/1992 Huston et al .
`........... 530/387.3
`7/1993 Winter ......... ........... 530/389.3
`6/1996 Queen el al. . ........... 530/387.3
`9/1996 Bendig el al. ... .. ...... 424/133.1
`12/1996 Queen el al. ............ 424/133. l
`t0/1997 Hudziak el al.
`........... 435n.23
`" 12/1997 Queen el al. ............ 530/387.2
`................... 435/69.6
`2/1998 Co et al.
`6/1998 Hudziak cl al.
`...... ... 424/130. l
`t0/ 1998 Carter el al. ............. 530/387.3
`11/1998 Lowman el al. ............ 5301399
`1/1999 Adair el al. ............. 530/387.3
`
`FOREIGN PATENT DOCUMENTS
`
`. .. ... .. . .. C07.K/15/12
`
`........... C12N/15/00
`
`......... A61.K/39/395
`
`AU
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`
`85058/91
`120694
`125023 Al
`0 239 400
`323806 Al
`328404 Al
`338745 Al
`365209 A2
`365997 A2
`368684
`403156 Al
`438310 A2
`438312 A2
`440351 A2
`0 460 167 Bl
`0 519 596 AL
`
`3/1992
`I0/1984
`11/1984
`* 9/1987
`7/1989
`8/1989
`10/1989
`4/1990
`5/ 1990
`5/1990
`12/ 1990
`7/1991
`7/1991
`8/1991
`12/1991
`12/1992
`
`EP
`EP
`EP
`EP
`EP
`GB
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`WO
`
`0 592 J06 AJ
`0 620 276
`682040 Al
`451216 Bl
`432249 Bl
`2 188941
`WO 87/02671
`WO 88/09344
`WO 89/01783
`WO 89/06692
`WO 89/09622
`WO 90/07861
`90/07861
`WO 91/07492
`WO 91/07500
`WO 91/09966
`WO 91/09968
`WO 91/09967
`WO 92/01047
`WO 92/04380
`WO 92/04381
`WO 92/05274
`WO 92/11383
`WO 92/11018
`WO 92/15683
`WO 92/16562
`WO 92/22653
`WO 93/02191
`94/11509
`WO 94/12214
`
`4/1994
`10/1994
`ll/1995
`1/1996
`9/1996
`10/1987
`5/1987
`12/1988
`3/1989
`7/1989
`10/1989
`7/1990
`* 7/1990
`5/1991
`5/1991
`7/ 1991
`7/1991
`11/1991
`1/1992
`3/1992
`3/1992
`4/1992
`7/1992
`9/1992
`9/1992
`10/1992
`12/1992
`2/1993
`5/1994
`6/1994
`
`........... C12P/21/08
`
`........... Cl2P/21/00
`
`........... CI2P/21/08
`........... Cl2P/21/08
`
`.......... A61 K/35/14
`
`OTHER PUBLICAI'IONS
`
`Riecbmaon et al. [ Nature 332:323-327 (1988)].*
`Queeo et al. [Proc. Natl. Acad. Sci. 86:10029-10033
`(1989)]. *
`Roill [Immunology, published 1985, by Gower Medical
`Publishing Ltd. (Lo111doo, England) p. 5.5].*
`Tramontano et al. [J. Mol. Biol. 215:175-182 (1990)].*
`"Biosym Technologies" in New Products, Chemical Design
`Automation 3 (Dec. 1988).
`" Polygen Corporation" in New Products, CbemicaJ Design
`Automation 3 (Nov. 1988).
`Adair et al., "Humanization of the murine anti-human CD3
`monoclonal antibody OKT3" Hum. Antibod. Hybridomas
`5:41-47 (1994).
`Cbotbia et al., "Principles of protein-protein recognitioo"
`Nature 256:705-708 (1975).
`Chothia el al., "Transmission of cooformatiooal change in
`iosulin" Nature 302:500-505 (1983).
`Corti et al., " Tdiotope Determining Regions of a Mouse
`Monoclonal Antibody and lls Humanized Versions" J. Mo!.
`Biol. 235:53-60 (1994) .
`
`(List continued on next page.)
`
`Primary Examiner-Anthony C. Caputa
`Assistant Examiner-Minh-Tam Davis
`(74) Attorney, Agent, or Firm-Wendy M. Lee
`
`(57)
`
`ABSTRACT
`
`Variant immunoglobulins, particularly bumaoized antibody
`polypeptides are provided, along with methods for their
`preparation and use. Consensus immunoglobulin sequences
`and structural models are also provided.
`
`82 Claims, 9 Drawing Sheets
`
`1 of 61
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`US 6,407,213 Bl
`Page 2
`
`OTHER PUBLICATIONS
`
`Couto et al., " Anti-l3A46 Monoclonal Antibody Mc3
`Humanization Using a Novel Positional Consensus and in
`Vivo and in Vitro Characterization" Cancer Research
`Supplement 55:1717-l 722 (1995).
`Couto et al., "Humanization of KC4G3, an Anti-Human
`Carcinoma Antibody" Hybrido111a 13:215-219 (1994).
`Ellis et al., "Engineered Anti-CD38 Monoclonal Anlibodies
`for l mmunotberapy of Multiple Myeloma" The Journal of
`l111munology pp. 925-937 (1995).
`Hieter el al., "Evolution of Human Immunoglobulin K J
`Region Genes" The Journal of Biological Che111isn:y
`257:1516-1522 (1982).
`Lesk, Arthur M., "How Different Amino Acid Sequences
`Determine Similar Protein Structures: The Structure and
`Evolutionary Dynamics of the Globins" J. Mot. Biol.
`135:225-270 (1980).
`in T4
`Matsumura et al., "Hydrophobic stabilization
`lysozyme determined directly by multiple substitutions of
`lie 3" Nature 334:406-410 (1988).
`Morrison, S. L., "Transfectomas Provide Novel Chimeric
`Antibodies" Science 229:1202-1207 (Sep. 20, 1985).
`Nakatani et al., "Humanization of mouse anti-human lL-2
`receptor antibody B-BlO" Protein Engineering 7:435-443
`(1994).
`Ohtomo el al., ·'Hu.manizatioo of Mouse ONS-M21 Anti(cid:173)
`body with the Aid of Hybrid Variable Regions" Molecular
`Immunology 32:407-416 (1995).
`Rodrigues et al., "Engineering a humanized bispecific
`F(ab')2 fragment for improved binding to T cells" Int. J.
`Cancer (Suppl.) 7:45-50 (1992).
`Sha et al., " A Heavy-Chain Grafted Anlibody that Recog(cid:173)
`nizes the Tumor-Associated TAG72 Antigen" Cancer Bio(cid:173)
`t!terapy 9:341-349 (1994).
`Tempest et al., " Identification of framework residues
`required to restore antigen binding during reshaping of a
`monoclonal antibody against the glycoprotein gB o( human
`cytomegalovirus" Int. J. Biol. Macromol. 17:37-42 (1995).
`Tramontano, '"Structural Determinants of the Conformations
`of Medium-Sized Loops in Proteins" Proteins 6:382-394
`(1989).
`Uchiyama el al., " A Monoclonal Antibody (Anti-Tac) Reac(cid:173)
`tive with Activated and Functionally Mature Human T
`Cells" Journal of Immunology 126:1393-1397 (1981).
`Vincenli et al., "Interleukio-2-Receptor Blockade with
`Daclizumab lo Prevent Acute Rejection in Renal Transplan(cid:173)
`tation" New Engl. J. Med. 338:161-165 (1998).
`Viletta el al., "Redesigning Nature's Poisons lo Create
`Anti-Tumor Reagents" Science 238:1098-1104 (1987).
`Waldmann et al., " Interleukin 2 Receptor (Tac Antigen)
`Expression in HTLV-1-associated Adult T-Cell Leukemia"
`Cancer Research 45:4559s-4562s (1985).
`Waldmann, Thomas A., "The Structure, Function, and
`Expression of Toterleukio-2 Receptors on Normal and
`Malignant Lymphocytes" Science 232:727-732 (1986).
`Wu et al., "An Analysis of the Sequences of the Variable
`Regions of Bence Jones Proteins and Myelorna Light Chains
`and Their Implications for Antibody Complementarity"
`Journal of Experimental Medicine 132:21.1-250 (1970).
`Rhodes, P., "Recombinant antibodies from CHO cells" Abstr
`Pap Am Chem Soc (Abstract No. 60 from the 199th Ameri(cid:173)
`can Chemical Society National Meeting held in Boston, MA
`Apr. 22-27, 1990) 199(1-2):BIOT 60 (Apr. 1990).
`
`Amzel and Poljak, "Three-<limeosiooal structure of immu(cid:173)
`noglobulios" Ann. Rel'. Bioc!te111. 48:961-967 (1979).
`Bindon et al., " Human monoclonal lgG isotypes differ in
`complement activating function al the level of C4 as well as
`Clq" Journal of Experimemal Medicine 168(1):127-142
`(Jul. 1988).
`Boulianne, G. L. el al., "Production of functional chimaeric
`mouse/human anlibody" Nature 312(5995):643-<546 (Dec.
`1984).
`Brown et al., "Anti-Tac-H, a humanized antibody Lo the
`interleukin 2 receptor, prolongs primate cardiac allografl
`survival" Proc. Natl. Acad. Sci. USA 88:2663-2667 (1991).
`Bruccoleri, "Structure of antibody hypervariable loops
`reproduced by a conformational search algorithm" Nature
`(erratum to article in Nature 335(6190):564-568 and)
`336:266 (1988).
`Bruggemann, M. et .al., "Comparison of the effector func(cid:173)
`tions of human immunoglobulins using a matched set of
`chimeric antibodies" Journal of Experimental Medicine
`166:1351-1361 (1987).
`.Burgess el al., " Possible Dissocialion of the Heparin-bind(cid:173)
`ing and Mitogenic Activities of Heparin-binding (Acidic
`Fibroblast) Growth Faclor-1 from Its Receptor-binding
`Activities by Site-directed Mutagenesis of a Single Lysine
`Residue" Journal of Cell Biology 111:2129-2138 (1990).
`Carter et al., "Humanization of an anti-p185I-LER2 antibody
`therapy'' Proc. Natl. Acad. Sci.
`for human cancer
`89:4285-4289 (1992).
`Cheetham, J., "Reshaping the antibody combining site by
`CDR replacement-tailoting or tinkering to fit?" Protein
`Engineering 2(3):170-172 (1988).
`Chothia and Lesk, "Canonical Structures for the Hypervari(cid:173)
`able Regions" J. Mo!. Biol. 196:901-917 (1987).
`Cholhia el al., "The predicted structure of immunoglobulin
`Dl.3 and its comparison with the crystal structure" Science
`233:755-758 (Aug. 15, 1986).
`Chotbia, C. et al., ·'Conformations of immuooglobulin
`bypervariable regions" Nature 342(6252):877-883 (1989).
`Cholbia, Cyrus, " Domain association in immunoglobulin
`molecules: The packing of variable domains" J. Mo!. Biol.
`186:651-<563 (1985).
`Clark et al., "Tbe improved lylic function and in vivo
`efficacy of monovalent monoclonal CD3 antibodies" Euro(cid:173)
`pean Journal of Immunology 19:381-388 (1989).
`Co el al., " Humanized antibodies for antiviral therapy" Proc.
`Natl. Acad. Sci. USA 88:2869-2873 (1991).
`Coussens et al., "Tyrosine Kinase Receptor with Extensive
`Homology to EGF Receptor Shares Chromosomal Location
`with oeu Oncogene" Science 230:1132-1139 (1985).
`Daugherty, BL et al., "Polymerase chain reaction facilitates
`the cloning, CDR-grafting, and rapid expression of a murine
`monoclonal antibody directed against the CD18 component
`integrins" Nucleic Acids Research
`of
`leukocyte
`19(9):2471-2476 (May 11, 1991).
`Davies, D.R. et al., "Antibody-Antigen Complexes" Ann.
`Rev. Biochem. 59:439-473 (1990).
`Epp el al., "The molecular structure of a dimer composed of
`lhe variable portions of the Bence-Jones protein REI refined
`at 2.0-A resolution" Biochemistry 14(22):4943-4952
`(1975).
`Fendly et al., ··Chara<:terization of rnurine monoclonal anti(cid:173)
`bodies reactive to either the human epidermal growth factor
`receptor or HER2/oeu gene product" Cancer Research
`50:1550-1558 (1990).
`
`2 of 61
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`US 6,407,213 Bl
`Page 3
`
`Furey et al., "Stnicture of a novel Bence-Jones protein
`(Rbe) fragment at 1.6 A resolution" J. Mo/. Biol.
`167(3):661-692 (Jul. 5, 1983).
`Gorman, SD et al., " Reshaping a therapeutic CD4 antibody"
`Proc. Natl. Acad. Sci. USA 88(l0):418l-4185 (May 15,
`1991).
`Gregory et al., "The solution conformations of the sub(cid:173)
`classes of human IgG deduced from sedimentation and small
`angle X-ray scattering studies" Molecular !111111unology
`24(8):821-829 (Aug. 1987).
`Hale et al., " Remis.sion induction in non-bodgkin lym(cid:173)
`phoma with
`reshaped human monoclonal antibody
`campath-lH" Lancet 1:1394-1399 (1988).
`Harris and Emery, "Therapeutic antibodies-the coming of
`age" Tibtech 11:42-44 (Feb. 1993).
`Huber et al., '"Crystallographic structure studies of an IgG
`molecule and an Fe fragment" Nature 264:415-420 (Dec. 2,
`1976).
`Hudziak et al., " pl85HEm Monoclonal Antibody Has Anti(cid:173)
`proliferative Effects In Vitro and Sensitizes Human Breast
`Tumor Cells to Tumor Necrosis Factor" Molecular & Cel(cid:173)
`lular Biology 9(3):1165-1172 (1989).
`Jal!ers, G. J. et al., "Monoclonal antibody therapy. Aoti-id(cid:173)
`iotypic and non-anti-idiotypic antibodies to OKT3 arising
`immunosuppres.sion" Transplantation
`despite
`intense
`41(5):572-578 (May 1986).
`Jones, P. T. et al., "Replacing the complementarity-deter(cid:173)
`mining regions in a human antibody with those from a
`mouse" Namre 321(6069):522-525 (1986).
`Junghans et al., "Aoti-Tac-H, a humanized antibody to the
`interleukin 2 receptor with new features for immunotherapy
`in maJignanl and immune disorders" Cancer Research
`50(5):1495-1502 (Mar. 1, 1990).
`Kabat et al. Sequences of Proteins of Immunological Inter(cid:173)
`est, Bethesda, MD:National Institutes of Health pp. iii-xx(cid:173)
`vii, 41-176 (1987).
`King et al., "Amplification of a Novel v-erbB-Related Gene
`in a Human Mammary Carcinoma" Science 229:974-976
`(1985).
`Lazar et al., "Transforming Growth Factor a: Mutation of
`Aspartic Acid 47 and Leucine 48 Results in Different
`Biological Activities" Molecular & Cellular Biology
`8(3):1247-1252 (1988).
`Love et al," Recombinant antibodies possessing novel effec(cid:173)
`tor functions" Methods in Enzymology 178:515-527 (1989).
`Lupu et al., "Direct interaction of a ligand for the erbB2
`oncogene product with t11e EGF receptor and pl85"'bB2'"
`Science 249:1552-1555 (1990).
`Margoi RA and Binaghi RA, " Nonprecipitating asymmetric
`antibodies" Ann. Rev. Immunol. 6:535-554 (1988).
`Margolies et al., " Diversity of light chain variable region
`sequences among rabbit antibodies elicited by the same
`antigens." Proc. Natl. Acad. Sci. USA 72:2180-84 (Jun.
`l975).
`Marquart et al., "Crystallographic refinement and atomic
`models of the intact irnnmnoglobulin molecule Kol and its
`antigen-binding fragment at 3.0 A and 1.0 A resolution" J.
`Mo!. Biol. 141(4):369-391 (Aug. 25, 1980).
`Miao, IS et al., "Structure, function and properties of anti(cid:173)
`body binding sites"./. Mo!. Biol. 217(1):133-151 (Jan. 5,
`1991).
`Miller, R. et al., " Monoclonal antibody therapeutic trials in
`seven patients with T--cell lymphoma" Blood 62:988-995
`(1983).
`
`Morrison, S. L. et al., "Chimeric human antibody molecules:
`mouse antigen-binding domains with human constant
`domains" Proc. Natl. Acad.
`Sci. USA
`region
`81(21 ):6851-6855 (Nov. 1984).
`Neuberger et al. , " Recombinant antibodies possessing novel
`effector functions" Nature 312(5995):604-608 (Dec. 1984).
`Neuberger, M. S. et al., "A hapten-specific chimaeric lgE
`antibody with human physiological effector function"
`Nature 314(6008):268-270 (Mar. 1985).
`Novotny and Haber, "Structuxal invariants of antigen bind(cid:173)
`ing: comparison of immunoglobulin YL-YN and YL-YL
`dimers" Proc. Natl. Acad.
`Sci. USA
`domain
`82(14):4592-4596 (Jul. 1985).
`Pluckthun, Andreas, "'Antibody engineering: advances from
`the use of Escherichia coli expression systems" Biotechnol(cid:173)
`ogy 9:545-51 (1991).
`Queen, M. et al., "A humanized antibody that binds to the
`receptor" Proc. Natl. Acad. Sci. USA
`interleukin 2
`86:10029-10033 (1989).
`Riecbmann, L. el aJ., " Reshaping human antibodies for
`therapy" Nature 332:323-327 (1988).
`Roin et al. !111munofogy (Gower Medical Publishing Ltd.,
`London, England) pp. 5.5 (1985).
`Saul et al., "Preliminary refinement and structural analysis
`of the Fab fragment from human immunoglobulin new at 2.0
`.Journal
`of Biol.ogical Chemistry
`A
`resolution"
`253(2):585-597 (Jan. 25, 1978).
`Schroff, R. el al., " Human anti-murioe immunoglobulio
`in patients receiving monoclonal antibody
`responses
`lli1:aapy" Carir.;er Reseurdc 45:879-885 (1985).
`Segal el al., "The three-dimensional structure of a phospho(cid:173)
`rylcholine-binding mouse immunoglobulin Fab and tbe
`oature of the antigen binding s ite" Proc. Natl. Acad. Sci.
`USA 71(11):4298-4302 (Nov. 1974).
`Shalaby et al., " Development of humanized bispecific anti(cid:173)
`bodies reactive with cytotoxic lymphocytes and tumor cells
`the HER2 protooacogene" Journal of
`overexpressing
`Experimental Medicine 175(1):217-225 (Jan. l, 1992).
`Shepard and Lewis, "Resistance of tu mor cells to tumor
`oecrosis factor''.!. Clin. lmmunol. 8(5):333-395 (1988).
`Sheri.ff et al., "Three-dimensional structure of an antibody(cid:173)
`complex" Proc. Natl. Acad.
`Sci. USA
`antigen
`84(22):8075-8079 (Nov. 1987).
`Sherman et al., " Haloperidol binding to monoclonal anti(cid:173)
`bodies" Journal of Biological Chemistry 263:4064-4074
`(1988).
`Silverton et al., "Tbree-dimensiooaJ structure of ao intact
`immunoglobulin" Proc. Natl. Acad. Sci. USA
`human
`74:5140-5144 (1977).
`Slamon et al., "Human Breast Cancer: Correlation of
`Relapse and Survival with Amplification of the HER-2/neu
`Oncogene" Science 235:177-182 (1987).
`Slamon et al., "Studies of tbe HER-2/ neu pro to-oncogene in
`human breast and ovarian cancer" Science 244:707-712
`(1989).
`Snow and Amzel, '·Calculating three-dimensional changes
`in protein structure due to amino-acid substitutions: the
`variable region of immunoglobulins" Protein: Sm1cture,
`Function, and Genetics, AJan R. Liss, Inc. vol. 1:267-279
`(1986).
`Sox et al., "Attachment of carbohydrate to the variable
`region of myeloma immunoglubulio light chains" Proc.
`Natl. Acad. Sci. USA 66:975-82 (Jul. 1970).
`
`3 of 61
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`US 6,407,213 Bl
`Page 4
`
`Spiegelberg et al., "Localization of the carbohydrate within
`tbe variable region of light and beavy cbains of human yG
`myeloma proteins" Biocliemist1y 9:4217-23 (Oct. 1970).
`Takeda el al., "Construction of chimaeric processed imnm(cid:173)
`noglobu lin genes containing mouse variable and human
`constant region sequences" Nature 314(6010):452-454
`(Apr. 1985).
`Tao et al., " Role of Carbobydrate in the Structure and
`Effector Functions Mediated by the H uman lgG Constant
`Region" J. Jmmunof. 143(8):2595-2601 (1989).
`Tramontano et al., "Framework residue 71 is a major deter(cid:173)
`minant of the position and conformation of the second
`hypervariable region in the VH domains of immunoglobu(cid:173)
`lins" J-Mof-Bio/ 215(1):175-182 (Sep. 5, 1990).
`Verhoeyeo, M. et al., "Reshaping human antibodies: grafting
`an antilysozyme activity" Science 239(4847):1534-1536
`(Mar. 25, 1988).
`Waldmann, T., " Monoclonal antibodies in diagnosis and
`tberapy" Science 252:1657-1662 (1991).
`Wallick et al., "G lycosylatioo of a VH residue of a mono(cid:173)
`clonal antibody against alpha (1--6) dextran increases its
`affinity for antigen" Journal of Experimental Medicine
`168(3):1099-1109 (Sep. 1988).
`Wiater and Milstein, "Man-made antibodies" Nature
`349(6307):293-299 (Jan. 24, 1991).
`Yamamoto et al., "Similarity of protein encoded by the
`human c-erb-B-2 gene to epidermaJ growth factor recep(cid:173)
`tor" Nature 319:230-34 (1986).
`Carter et al., " High level escl1erichia coli expression and
`production of a bivalent bumanized antibody fragment"
`Bio/Technology 10: 163-167 (1992).
`Foote et al., "Antibody Framework Residues Affecling the
`Conformation of the Hypervariable Loops" J. Mo!. Biol.
`224:487-499 (1992).
`Foote, J ., "Humanized Antibodies" Nova acra Leopoldina
`61(269):103-110 (1989).
`Kabat et al., "Sequences of Proteins of immunological
`Interest'', Betbesda, MO:National Institute of Health pp.
`14-32 (1983).
`Kettleborougb et al., " Humanization of a Mouse Mono(cid:173)
`the Importance of
`clonal Antibody by CDR-grafting:
`Framework Residues on Loop Conformation" Protein Engi(cid:173)
`neering 4(7):773-783 (1991).
`Maeda et al., "Construction of Reshaped Human Antibodies
`witb HIV-neu tralizing Activity" Hum. Antibod. Hybrido(cid:173)
`mas 2:124-134 (Jul. 1991).
`Riechmann et al, "Expression of an Antibody Fv Fragment
`in Myelorna Cells" J. Mo/. Biol. 203:825-828 (1988).
`Routledge et al., "A Humanized Monovalent CD3 Antibody
`which Cao Activate Homologous Complement" European
`Journal of Immunology 21:2717-2725 (1991).
`Shearman et al., "Construction, Expression and Character(cid:173)
`ization of Humanized Antibodies Directed Against the
`Jmmunol.
`Human
`a/~ T
`Cell
`Receptor"
`./.
`147(12):4366-4373 (Dec. 15, 1991).
`Ternpest et al., " Reshaping a Human Monoclonal Antibody
`to Inhibit Human Respiratory Syncytial Virus Infection In
`Vivo" Bio/Technology 9:266-271 (Mar. 1991).
`Brown, Jr. cl al., "Aali-Tac-H, a humanized antibody to the
`interleukin 2 receptor, prolongs primate cardiac allograft
`survival" Proc. Natl. Acad. Sci. USA 88:2663-2667 (1991).
`Casale et al., "Use of an anti-IgE humanized monoclonal
`antibody in ragweed-induced allergic rhinitis" J. Allergy
`C!in. Jmmunol 100: 110-121 (1997).
`
`Fahy et al., "The Effect of an Anti-lg£ Monoclonal Anti(cid:173)
`body on tbe Early- and Late-Pbase Responses to Allergen
`Inhalation in Asthmatic Subjects" Am J. Respil: Crit. Care
`Med 155:1828-1834 (1997).
`Mathieson et al., "Monoclonal-Antibody Therapy in Sys(cid:173)
`temic Vasculitis" New England.!. of Medicine pp. 250-254
`(Jul. 1990).
`Presta et al., "Humaoizatioo of an anti-vascular endothelial
`growth factor monoclonal antibody for the therapy of solid
`disorders" Cancer Research
`tumors
`and
`other
`57(20):4593-4599 (Oct. 15, 1997).
`Amit et al., "Three-Dimensional Structure of an Anti(cid:173)
`gen-Antibody Complex at 2.8 A Resolution" Science
`233:747-753 (Aug. 1986).
`Amzel et al., "'The Three Dimensional Structure of a Com(cid:173)
`bining Region-Ligand Complex of lrnmunglobulin New at
`3.5-A Resolution" Proc. Na1/. Acad. Sci. USA
`71(4):1427-1430 (Apr. 1974).
`Baselga et al., "Pbase IT Study of Weekly Intravenous
`Recombinant Humanized Anti-p185/HER2 Monoclonal
`Antibody
`in Patients With HER2/neu-Overexprcssing
`Metastatic Breast Cancer" J. Clin. Oncol. 14(3):737-744
`(1996).
`Beverley & Callard, "Distinctive functional charcteristics of
`human "T'' lymphocytes defined by E rosetting or a mono(cid:173)
`clona 1 anti-T cell antibody" European Journal of lnununol(cid:173)
`ogy 11:329-334 (1981).
`Bird et al., "Single-chain antigen-binding proteins" Science
`242:423-426 (Oct. 1988).
`B rennan ct al., "Preparation of bispccific antibodies by
`chemical recombination of monoclonal immunoglobulin 0 1
`fragments" Science 229:81-83 (Jul. 1985).
`Bruccoleri et al., "Structure of antibody bypervariable loops
`reproduced by a conformational search algorithm" Nature
`335:564-568 (Oct. 1988).
`Caron et al., "Biological and Immunological Features of
`Humanized Ml95 (Anti-CD33) Monoclonal Antibodies"
`Cancer Research 52:6761-6767 (Dec. 1992).
`Chothia & Lesk, "The relation between the divergence of
`in proteins" EMBO Journal
`sequence and structure
`5(4):823-826 (1986).
`Co & Queen, "Humanized antibodies for therapy" Nature
`351:501-502 (Jun. 1991).
`Co et al., "Chimeric and Humanized Antibodies with Speci(cid:173)
`./. of Immunology
`fici ty
`for
`the CD33 Antigen"
`148(4):1149-1154 (Feb. 1992).
`Co et al., " Humanized Anti-Lewis Y Antibodies: Tn Vitro
`Properties and Phannacokinetics in Rhesus Monkeys" Can(cid:173)
`cer Research 56:1118-1125 (Mar. 1996).
`Colman et al., "Crystal and Molecular Structure of the
`Dimer of Variable Domains of the 13ence-Jones Protein
`ROY" J. Mo!. Biol. 116:73-79 (1977).
`Colman el al, "Three-climensionaJ structure of a complex of
`antibody with influenza virus neuraminidase" Nature
`326:358-363 (Mar. 1987).
`Cook et al., " A map of the human immunoglbulin V H locus
`completed by analysis of the telometric region of chromo(cid:173)
`some 14q" Nature Genetics 7:162-168 (Jun. 1994).
`five
`Darsley & Rees,
`"Nucleotide
`sequences of
`anti-lysozyme monoclonal antibodies" EMBO Journal
`4(2):393-398 (1985).
`Davies & Metzger, "Structural Basis of Antibody Function"
`Ann. Rev. I111111unol. 1:87-117 (1983).
`
`4 of 61
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`US 6,407,213 Bl
`Page 5
`
`Davies et al., "Aotibody-Aotigen Complexes" Journal of
`Biological Chemistry 263(22):10541-10544 (Aug. 1988).
`Eigenbrot et al., "X-Ray Structures of Fragments From
`Binding and Nonbinding Versions of a Humanized
`Anti-CD18 Antibody: Structural Indications of the Key
`Role of V" Residues 59 to 65" Proteins 18:49-62 (1994).
`Eigenbrot et al., "X-ray strnctures of the antigen-binding
`domains from three variants of humanized anli-pl85HER2
`antibody 4D5 and comparison with molecuJar modeling" J.
`Mo!. Biol. 229:969-995 (1993).
`Ellison et al., "The nucleotide sequence of a human immu(cid:173)
`gene" Nucleic Acids Research
`noglobuLin Cyl
`10(13):4071-4079 (1982).
`Emery & Adair, ·'Humanised monoclonal antibodies for
`therapeutic applications" Exp. Opin.
`Invest. Drugs
`3(3):241-251 (1994).
`Epp et al., "Crystal and Molecular Structure of a Dimer
`Composed of the Variable Portions of the Bence-Jones
`Protein REI" European.Journal of Bioche111istry145:513-524
`(1974).
`Fanger et al., " Bispecific antibodies and targeted cellular
`cytotoxicity" Immunology Today 12(2):51-54 (1991).
`Fanger et al., "Cytotoxicily mediated by human Fe receptors
`for lgG" Immunology Today 10(3):92-99 (1989).
`Feldmann el al., " A Hypothetical Space-Filling Model of
`tbe V-Regions of the Galactan-Binding Myeloma Immu(cid:173)
`noglobulin ) 539" Molecular Immunology 18(8):683-698
`(1981).
`Pendley et al., "The Extracellular Oomain of HER2/neu Is a
`Potential lmmunogen for Active Specific lmmunotberapy of
`Breast Cancer" J. Biol. Resp. Mod. 9:449-455 (1990).
`Glennie et al., "Preparation and Performance of Bispecific
`F( ab'y)2 Antibody Containing Thiocther-Linked Fab'y Frag(cid:173)
`ments" J. Immunol. 139(7):2367-2375 (Oct. 1, 1987).
`Gonzalez et al., "Humanization of Murine 6G425:Ao
`Aoti-IL8 Monoclonal Antibody Wbicb Blocks Binding of
`IL8 to Human Neutrophils" 1996 Keystone Symposia on
`Exploring and Exploiting Antibody and lg Supe1jamily
`Combining Sites (Poster) pp. 1-21 (Feb. 1996).
`Gussow & Seemann, " Humanization of Monoclonal Anti(cid:173)
`bodies" Meth.. Enzymology, Academic Press, Inc. vol.
`203:99-121 (1991).
`Hieter et al., "Cloned human and mouse kappa immunoglo(cid:173)
`bulin constant and J region genes conserve homology in
`functional segments" Cell 22 (Part 1):197-207 (1980).
`Houghton, A., " Building a better monoclonal antibody"
`Immunology Today 9(9):265-267 (1988).
`Huston et al.," Protein engineering of antibody binding sites:
`Recovery of specific activity in an anti-cligoxin single-chain
`Fv analogue produced in Escherichia coli" Proc. Natl.
`Acad. Sci. USA 85:5879-5883 (Aug. 1988).
`Isaacs et al., " Humanised Monoclonal Antibody Therapy for
`Rheumatoid Arthritis" Lancet 340:748-752 (Sep. 26, 1992).
`Johnson et al., " Biological and Molecular Modeling Studies
`Comparing Murine MonoclonalAotibodics with Their Engi(cid:173)
`neered Chimeric and Humanized Counterparts" J. Cell.
`Biochem. Suppl 0 (13 Part A) (18th Aon. UCLA Syrop on
`Mol. & Cell. Biol., Park City, UT Jan. 17-22, 1989) pp. 87
`(1989).
`Kabat E., " Origins of Antibody Complementarity and Speci(cid:173)
`ficity-Hypervariable Regions and the Minigenen Hypoth(cid:173)
`esis" J. of Immunology 125(3):961-969 (Sep. 1980).
`
`Kabat et al. Sequences of Proteins of Immunological Inter(cid:173)
`est, U.S. Dept. of Health and Human Services, NIH, Sib
`edition vol. 1:103-108, 324-331 (1991).
`Kindt & Capra 111e Antibody Enigma, New York:Plenum
`Press pp. 79-86 (1984).
`Lesk & Chothia,
`·'Evolution of Proteins Formed by
`P-Sheets" .l. Mot. Biol. 160:325-342 (1982).
`Lesk & Chotbia, "Tbe response of protein structures to
`amino-acid sequence changes" Ph.ii. Trans. R. Soc. Lond. A
`317:345-356 (1986).
`Mariuzza et al., "Tbe Structure Basis of Antigen-Antibody
`Recognition" Ann. Re1J. Biophys. Biophys. Chem.
`16:139-159 (1987).
`Nadler et al., " lmrounogeoicity of Humanized and Human
`Monoclonal Antibodies" Clin. Pharmacology & Therapeu(cid:173)
`tics pp. 180 (Feb. 1994).
`Nelson, H., "Targeted Cellular Jmmunotherapy with Bifonc(cid:173)
`Lional Antibodies" Cancer Cells 3:163-172 (1991).
`Neuberger et al., "Antibody Engineering" Proceedings 8th
`Intl. Biotech. Symp., Paris II:792-799 (1988).
`Newmark, P., ·'Making Chimeric Antibodies Even More
`Human" Bio/Technology 6:468 (May 1988).
`Nisbimura et al., "Human c-erbB-2 Proto-Oncogene Prod(cid:173)
`uct as a Target for Bispecific-Aotibody-Directed Adoptive
`Tumor Immunotherapy" Int. J. Cancer 50:800-804 (1992).
`Nitta et a.I., "Preliminary trial of specific targeting therapy
`against malignant glioma" Lancet 335(8686):368-371 (Feb.
`17, 1990).
`Nitta, T. et al., "Bispecific F(ab')2 monomer preparecl with
`anti-CD3 and anti-numor monoclonal antibodies is most
`potent in induction of cytolysis of human T cells" European
`Journal of Immunology 19:1437-1441 (1989).
`Nolan et al., "Bifunctional antibodies: concept, production
`and applications" Biochimica et Biophysica Acta 1040:1-11
`(1990).
`O'Connor et al., "Calcium Dependence of an Anti-Protein C
`Humanized Antibody
`Involves Framework Residues"
`(manuscript).
`Orlandi et al., "Cloning Immunoglobulin Variable Domains
`for Expression by tbe Polymerase Chain Reaction" Proc.
`Natl. Acad. Sci. USA 86:3833-3837 (May 1989).
`Orlandi et al., "Cloning of cDNA Corresponding to Heavy
`and Light Chain lmmuooglobulin Variable Domains" Pro(cid:173)
`lein and Plumnaceuri.cal Engineering pp. 90 (1989).
`Ostberg & Queen, " Human and humanized monoclonal
`antibodies: preclinical studies and clinical experience" Bio(cid:173)
`chem. Soc. Transactions pp. 1038-1043 (1995).
`Pedlan et al., " Model-building Studies of Antigen-binding
`Sites:The Hapten-binding Site of MOPC-315" Cold
`Springs Harbor Symposia On Quantitative Biology
`XU:627-637 (1977).
`Pad Ian, E., "Anatomy of the Antibody MolecuJe" Molecular
`Immunology 31(3):169-217 (1994).
`Padlao, E., "Evaluation of the Structural Variation Among
`Light Chain Variable Domains" Molecular Immunology
`16:287-296 (1979).
`Palm & Hilschruann, "Primary structure of a crystalline
`monoclonal immunoglobulin K-type L-cbain, subgroup I
`(Bence-Jones preotia Rei); isolation & characterization of
`the tryptic peptides: . . . " Hoppes-Seyler's Z. Physiol.
`Chem. 356:167-191 (Feb. 1975).
`
`5 of 61
`
`Celltrion, Inc., Exhibit 1001
`
`

`

`US 6,407,213 Bl
`Page 6
`
`Palm & Hilschmann, "Tbe primary structure of a crystalline,
`monoclonal immunoglobulin-L-chain of the x-type, sub(cid:173)
`group I (Bence-Jones Protein Rei): a contribution to the
`elucidation of tbe tbree--dimeasional structure of tbe imam(cid:173)
`z.
`aoglobulins" Hoppe-Seyler's
`Physiol.
`Chem.
`354:1651-1654 (Dec. 1973).
`Paoka et al., "Variable region framework differences result
`in decreased or increased affinity of variant anti--digoxin
`antibodies" Proc. Natl. Acad. Sci. USA 85:3080-3084 (May
`1988).
`Presta et al., " Humanization of an Antibody Directed
`Against lgE" ./. lmmunol. 151(5):2623-2632 (Sep. 1, 1993).
`Preval & Fougereau, "Specific [nteraction between V H and
`VL Regions of Human Monoclonal lmmunoglobulins" J.
`Mot. Biol. 102:657-678 (1976).
`Queen et al., ·'Construction of Humanized Antibodies and
`1estiog io Primates" J. Cell. Biochem. Suppl. 15 (Part E)
`(20th Ann. Mtg. Keystone Symp. Denver, CO Mar. 10-16,
`1991) pp. 137 (1991).
`Queen et al., "Humanised antibodies to the TL-2 receptor"
`Protein Eng. Antibody Mo!. Prophyl. Ther. Appl. Man,
`Clark, M., Nottingham, UK:Academic Titles pp. 159-170
`(1993).
`Rhodes & Birch, "Large-Scale Production of Proteins from
`Mammalian Cells" Bio/Teclmology 6:518, 521, 523 (May
`1988).
`Riechmann, "Humanizing of Recombinant Antibodies"
`(Intl. Syrop. on Clio. Appl. of Monoclonal Antibodies,
`Guildford, England) pp. 33-34 (Sep. 1987).
`Riecbmann & Wiater, " Recombinant Antibodies" (U. of
`London Royal Postgraduate Medical School, Wolfson Iosti(cid:173)
`tute, Abstract) (May 1987).
`Riecbmano et al. Alignment of VL Sequences (1988).
`Roberts & Rees, "Generation of an antibody with enhanced
`affinity and specificity for its antigen by protein engineer(cid:173)
`ing" Nature 328:731-734 (Aug. 1987).
`Rostapsbov et al., "Effective method for obtaio.iog long
`nucleotide chains oo partially complementary templates"
`FEBS Letters 249(2):379-382 (.Jun. 1989).
`Schneider et al., "The Aoti-ldiotypic Response by Cyno(cid:173)
`molgus Mondkeys to Humanized Anti-Tac Ts Primarily
`Directed to Complementarity-Determining Regions Hl, H2,
`and L3" .!. of Immunology 150:3086-3090 (Apr. 1993).
`in Tumor
`Sedlacek et al., "Monoclonal Antibodies
`Therapy", Karger pp. 119-126, 133-179 (1988).
`Shields et al., " Inhibition of Allergic Reactions with Anti(cid:173)
`bodies to TgE"